Many cases of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are characterized by an activating point mutation of JAK2 (JAK2 V617F ). It has been generally accepted that JAK2 V617F -positive cells outpace normal hematopoietic cells as a result of constitutively active growth factor signaling 1 ; however, failure of JAK2 V617F to confer a significant competitive advantage over normal hematopoiesis in 2 independent knock-in MPN models 2, 3 suggests that additional factors may be required to promote expansion of JAK2 V617F -positive cells in patients.
Introduction
Many cases of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are characterized by an activating point mutation of JAK2 (JAK2 V617F ). It has been generally accepted that JAK2 V617F -positive cells outpace normal hematopoietic cells as a result of constitutively active growth factor signaling 1 ; however, failure of JAK2 V617F to confer a significant competitive advantage over normal hematopoiesis in 2 independent knock-in MPN models 2, 3 suggests that additional factors may be required to promote expansion of JAK2 V617F -positive cells in patients.
As MPN patients overproduce certain proinflammatory cytokines known to suppress normal hematopoiesis, 4 it is conceivable that JAK2 V617F may protect mutant stem cells and progenitors from the apoptotic cues induced by these cytokines.
In this context, we recently observed that TNF␣ levels are elevated in mice with retrovirally induced JAK2 V617F MPN. 5 The physiologic effects of TNF␣ are complex and cell type-dependent, ranging from stimulation of proliferation to induction of apoptosis. 6 TNF␣ negatively regulates the expansion and self-renewal of pluripotent hematopoietic stem cells (HSCs) 7, 8 and has inhibitory effects on normal as well as some leukemic human hematopoietic progenitor cells. [9] [10] [11] TNF␣'s involvement in the evolution of leukemia is not without precedent. Studies in Fanconi anemia (FA) have implicated TNF␣ hypersensitivity as a central mechanism of clonal evolution and progression to acute myeloid leukemia. In the FA Complementation Group C murine model (Fancc Ϫ/Ϫ ) TNF␣ induces bone marrow failure 12 and can promote the evolution of somatically mutated TNF␣-resistant preleukemic stem cell clones. 13 Taking into account TNF␣'s role in clonal evolution and that elevated TNF␣ levels are present in human MPN we hypothesized that JAK2 V617F induces TNF␣ expression and simultaneously confers TNF␣ resistance to MPN progenitor cells.
Methods

Isolation and culture of primary cells
Blood mononuclear cells (MNCs) were obtained from peripheral blood samples of patients with polycythemia vera (PV) and essential thromobocythemia (ET), myelofibrosis (MF), or normal volunteers. CD34 ϩ cells were obtained from bone marrow of normal, PV and ET patients or peripheral blood of MF patients. All patients gave their informed consent in accordance with the Declaration of Helsinki to participate in the study, which was approved by the Institutional Review Boards of Oregon Health
Cell separation and human hematopoietic colony assays
Peripheral blood and bone marrow MNC were isolated by density gradient centrifugation using Ficoll (Nycomed). Lysis of residual red blood cells (RBCs) was accomplished with Ammonium Chloride Lysing (ACK) buffer. For colony formation assays using MNCs, cells were plated in triplicate in methylcellulose culture at a density of 1 ϫ 10 5 cells/mL. For CD34 ϩ colony formation assays MNCs were incubated with anti-human CD34 microbeads (Miltenyi) and column purification was performed according to the manufacturer's protocol. After confirmation of Ͼ 92% purity by flow cytometry using a FACS Aria II (BD Biosciences) cells were plated at a density of 4000 cells/mL (in triplicate) in Methocult H4320 (StemCell Technologies), supplemented with human erythropoietin (hEPO; Procrit, Amgen) at the concentration described in each figure, 10 ng/mL human IL-3 (hIL-3; Peprotech) and 50ng/mL human stem cell factor (hSCF; Peprotech) Ϯ 1, 10 or 100 ng/mL human TNF␣ (R&D Systems). Plates were incubated at 37°C in a 5% CO 2 95% air mixture in a humidified incubator for 12 days. Hematopoietic colonies were scored by standard morphologic criteria using an inverted microscope.
Genotyping of hematopoietic colonies
Individual colonies were harvested at day 12 into 100 L deionized water. Genotyping was performed by PCR followed by digestion with BsaXI (New England BioLabs) as previously described. 14 
TNF␣ ELISA
Peripheral blood was collected into EDTA and centrifuged for 15 minutes at 1000g within 30 minutes of collection. The resulting plasma was removed and stored at Ϫ80°C until quantification. TNF␣ ELISA was performed using Quantikine HS (R&D Systems) according to the manufacturer's protocol.
Pharmacologic inhibitors of JAK2
The JAK2 inhibitors CYT387 5, 15 and TG101209 16 were kindly provided by YM Biosciences and TargeGen, respectively. RNA extraction, cDNA synthesis, and qPCR RNA was extracted by using the RNeasy mini kit (QIAGEN) with subsequent DNaseI digestion procedure according to the manufacturer's instructions. Samples were then either stored at Ϫ80°C or subsequent cDNA synthesis was performed using the SuperScript III First-Strand synthesis system for RT-PCR (Invitrogen) according to the manufacturer's instructions. qPCR was performed on an Opticon2 DNA Engine (MJ Research) using dual hybridization probes (Light Cycler 480 Probes Master; Roche). GAPDH was used as a reference gene using the human/ murine GAPDH probe #9, the murine TNF␣ probe #49, and the human TNF␣ probe #29 (all from Universal Probe Library; Roche).
The following primer pairs were used: murine TNF␣ forward: 5Ј-TGCCTATGTCTCAGCCTCTTC-3Ј; murine TNF␣ reverse: 5Ј-GAGGC-CATTTGGGAACTTCT-3Ј; murine GAPDH forward: 5Ј-AGCTTGTCAT-CAACG GGAAG-3Ј; murine GAPDH reverse: 5Ј-TTTGATGTTAGT-GGGGTCTCG -3Ј; human TNF␣ forward; 5Ј-TCAGCCTCTTCTCCT-TCCTG-3Ј; human TNF␣ reverse: 5Ј-TCAGCTTGAGGGTTTGCTAC-3Ј; human GAPDH forward: 5Ј-AACGGGAAGCTTGTCATCAA-3Ј; human GAPDH reverse: 5Ј-TGGACTCCACGACGTACTCA-3Ј. PCR cycling conditions were as follows: initial denaturation at 95°C for 5 minutes, followed by 50 cycles at 95°C for 10 seconds, 60°C for 50 seconds, and 72°C for 10 seconds, followed by a 10 minute terminal incubation at 72°C. Expression of target genes was measured in triplicates and was normalized to GAPDH.
TNF allele burden assay
The JAK2 V617F real-time quantitative PCR (qPCR) assay was developed using allele specific PCR (AS-PCR) primers 14 for distinguishing wild-type from mutant alleles, and fluorescent resonance energy transfer (FRET) probes (with melting curves) for accurate and sensitive allele burden quantitation. The assay consisted of 2 separate qPCR reactions for the quantification of the wild-type and mutant alleles. For the mutant allele, the 12.5 l reaction consists of 25 ng of genomic DNA, 1ϫ LightCycler 480 Genotyping master mix (Roche), 200nM each of sensor (5Ј -TTTTCCTTAGTCTTTCTTTGAAGCAGCAAGTA-FTIC) and anchor (5Ј LC Red 640 -ATGAGCAAGCTTTCTCACAAGCATTTGGTTTTAAPhosphate) probes, and 500nM each of forward (5Ј-GAACTATTTATG-GACAACAGTCA) and reverse (5Ј -GTTTTACTTACTCTCGTCTCCACAaAA) primers. For the wild-type allele, the 12.5 L reaction consists of 25 ng of genomic DNA, 1ϫ Genotyping master mix (Roche), 200nM each of sensor (5Ј -CTTTCTCAGAGCATCTGTTTTTGTTTATATAGAAA -FTIC) and anchor (5Ј LC Red 640 -TCAGTTTCAGGATCACAGCTAG-GTGTCAG -Phosphate) probes, and 500nM each of forward (5Ј-GCATTTGGTTTTAAATTATGGAGTATaTG) and reverse (5Ј -ATACTTA-ACTCCTGTTAAATTATAGTTTAC) primers. The probes were designed using LightCycler Probe Design Version 2 (Roche). The lower case letters in primers are intentional mismatch for better specification. Both assays have demonstrated no cross-reactivity with their counterpart cell lines (HEL expresses V617F vs CEM expresses wild-type). The V617F allele burden was measured by the Advanced Relative Quantification method using Second Derivative maximum method and PCR efficiency correction, and was reported as a ratio of the mutant allele divided by the sum of the wild-type and mutant alleles.
Expression vectors
The murine JAK2 V617F -MSCV-IRES-GFP vector was kindly provided by Dr Ross Levine (Memorial Sloan-Kettering Cancer Center, New York, NY).
Bone marrow transplantation
TNF␣ knock-out mice (B6;129S-Tnf tm1Gkl /J (stock 003008) and B6.129S-Tnf tm1Gkl /J (stock 005540)) and their respective wild-type equivalents (B6129SF2/J and C57B/6J) were purchased from The Jackson Laboratory. Retroviral infection and transplantation was performed as previously described. 17 All mouse work was performed with approval from the OHSU and Portland VA Medical Center Institutional Animal Care and Use Committee.
Murine colony formation assays
Hematopoietic progenitors (lineage negative , c-kit ϩ Sca-1 Ϫ ) were sorted using a FACS Aria II (BD Biosciences) from wild-type C57B/6J mice or Fancc Ϫ/Ϫ bone marrow and subjected to 2 rounds of spinoculation as previously described. 17 GFP ϩ cells were then sorted and plated in triplicate at 500 cells/mL into M3230 methylcellulose (StemCell Technologies) supplemented with 50 ng/mL mSCF, 10 ng/mL mIL-3 (Peprotech), 5 U/mL hEPO (Amgen), Ϯ mTNF (R&D Systems). Cells were enumerated at day 12, with visual confimation of GFP positivity for each colony.
Statistical analysis
Mean values Ϯ SEM are shown unless otherwise stated. Student t test, Pearson correlation, or Mann-Whitney was used for comparisons (GraphPad Prism Version 5.0).
Results
MPN is associated with increased plasma levels of TNF␣
We have previously shown that TNF␣ concentrations are elevated in mice with experimentally induced JAK2 V617F MPN compared with controls and reduced on treatment with CYT387, a JAK2 kinase inhibitor. 5 In initial experiments we measured plasma TNF␣ in MPN patients and healthy controls ( Figure 1A ). Median TNF plasma concentrations in MF, PV and ET patients were 10, 5 and 4-fold higher than in controls (P Ͻ .0001, Ͻ .0001 and ϭ .0031, respectively). Similarly we found 2-fold higher TNF␣ mRNA expression in peripheral blood white blood cells from an independent group of PV patients compared with normal controls BLOOD, 8 DECEMBER 2011 ⅐ VOLUME 118, NUMBER 24 For personal use only. on April 9, 2017. by guest www.bloodjournal.org From (P Ͻ .0004; Figure 1B ). These data show that TNF␣ is increased in MPN, but do not specifically delineate whether the increase in TNF is a direct consequence of JAK2 V617F .
JAK2 V617F allele burden and kinase activity correlate with expression of TNF
To identify a potential correlation between JAK2 V617F and TNF␣ expression, we quantified JAK2 V617F allele burden in 20 JAK2 V617F -positive patients included in the TNF␣ plasma concentration analysis ( Figure 1C ). TNF␣ plasma concentration was found to correlate with JAK2 V617F allele burden (Pearson r ϭ 0.7185, R 2 ϭ 0.5762, P ϭ .004). Consistent with the observed correlation between JAK2 V617F and TNF␣ expression in primary human samples, splenocytes from a murine transduction/transplantation model of JAK2 V617F MPN express increased levels of TNF␣ mRNA at baseline and produce exaggerated amounts of TNF␣ in response to LPS (supplemental Figure 1) . To further validate the association between JAK2 V617F and TNF␣ expression we compared TNF␣ mRNA in human hematopoietic cell lines either with or without the JAK2 V617F mutation ( Figure 1D ). TNF␣ mRNA levels in HEL cells (homozygous for JAK2 V617F and containing multiple copies of the gene) were elevated compared with all evaluated JAK2 WT lines, supporting the notion that TNF␣ expression is positively regulated by JAK2 V617F . To confirm that TNF␣ expression is regulated by JAK2 kinase activity, we treated TNF expressing cell lines with the JAK2 inhibitors CYT387 5,15 ( Figure  1E ) or TG101209 16 (supplemental Figure 2) and observed a time-dependent reduction of TNF␣ in the JAK2 V617F -positive HEL cells, while CYT387 did not decrease TNF␣ mRNA expression in JAK2 WT HL60 cells. 18 JAK2 inhibition decreased TNF␣ mRNA in both MPN and normal blood MNC, although the effect was more pronounced in MPN samples ( Figure 1F ). These data show that JAK2 V617F regulates TNF␣ expression in primary cells and JAK2 V617F cell lines and accentuates physiologic JAK2-mediated TNF expression.
Differential effects of TNF on MPN and normal hematopoietic progenitor cells
TNF␣ levels are high in MPN patients yet JAK2 V617F -positive cells exhibit dramatic expansion in this environment. Therefore to assess possible differential effects of TNF␣ on normal versus MPN progenitor cells we performed clonogenic assays on MNC in the presence of graded concentrations of EPO and TNF␣ (Figure 2A ). Low TNF␣ concentrations (1ng/mL) increased BFU-E formation by MPN cells, but reduced BFU-E formation by normal MNC. Intermediate and high TNF␣ concentrations (10 and 100 ng/mL) decreased BFU-E and CFU-GM formation in both MPN and normal samples, but colony survival was consistently lower in For personal use only. on April 9, 2017. by guest www.bloodjournal.org From normal controls. To minimize potential effects mediated through bystander cells within the MNC population we also assayed CD34 ϩ cells ( Figure 2B ). In normal controls, 10 ng/mL TNF␣ suppressed BFU-E and CFU-GM colony formation by Ͼ 50%. In striking contrast, CFU-GM colony formation by MPN CD34 ϩ progenitors was paradoxically enhanced by TNF␣ (P Ͻ .0001), and BFU-E formation was relatively resistant to TNF␣ (P ϭ .08). These findings suggest that the differential response to TNF␣ may contribute to MPN pathogenesis by conferring a selective growth advantage to JAK2 V617F -positive MPN cells in the TNF␣ rich environment of MPN patients.
To test whether TNF␣ favors growth of JAK2 V617F colonies in individual MPN patients, we genotyped individual colonies grown with and without 10 ng/mLTNF␣. TNF␣ consistently selected for JAK2 V617F colonies and in some cases completely eliminated JAK2 WT colonies (Figure 3 ). This effect was noted both in BFU-E and CFU-GM (supplemental Figure 3) , demonstrating that JAK2 V617F clones enjoy a selective advantage in the presence of TNF␣.
The preneoplastic CD34 ؉ cell compartment of MPN patients is hypersensitive to TNF
We used the colony formation and genotyping data to separately calculate the effect of TNF␣ specifically on the preneoplastic (JAK2 WT ) and neoplastic (JAK2 V617F ) CD34 ϩ compartment of individual JAK2 V617F -positive patients. JAK2 WT preneoplastic progenitors from JAK2 V617F -positive MPN patients were much more sensitive to TNF␣ than normal controls (82 Ϯ 23% vs 57 Ϯ 10% reduction, P ϭ .01; Figure 4 ), demonstrating that JAK2 WT progenitor cells from JAK2 V617F -positive MPN patients are intrinsically hypersensitive to TNF␣.
Ectopic expression of JAK2 V617F protects murine hematopoietic progenitors from TNF␣
To formally determine whether JAK2 V617F expression is sufficient to confer TNF␣-resistance we expressed JAK2 V617F or empty vector in normal hematopoietic progenitor cells (lineage neg c-kit ϩ Sca-1 Ϫ ), and assessed colony formation in the presence of TNF␣. JAK2 V617F induced TNF␣ resistance ( Figure 5A ). The protective effect of ectopically expressed JAK2 V617F was confirmed in TNF␣-hypersensitive Fancc Ϫ/Ϫ progenitor cells ( Figure 5B ), which are intrinsically hypersensitive to TNF. 19 These results show that JAK2 V617F imparts TNF␣-resistance to normal hematopoietic progenitors as well as progenitors with intrinsic TNF␣ hypersensitivity, suggesting that TNF␣ produced by MPN cells promotes their expansion at the expense of nonneoplastic hematopoiesis. Colony formation in 0 ng/mL TNF␣ is normalized to 100%. (B) Effect of TNF␣ on colony formation from CD34 ϩ cells. CD34 ϩ cells from MPN (n ϭ 16 for 10 ng/mL TNF␣, n ϭ 3 for 1 ng/mL TNF␣) and normal controls (n ϭ 6 for 10 ng/mL TNF␣, n ϭ 3 for 1 ng/mL TNF␣) were plated in methylcellulose media supplemented with SCF, IL-3 and 5 U/mL EPO, with graded concentrations of TNF␣ (in triplicate). 
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TNF␣ facilitates expansion of JAK2 V617F cells in a murine transplantation model of MPN
To determine to which degree disease initiation and marrow harvested from 5-fluorouracil (5-FU) treated TNF␣ Ϫ/Ϫ and TNF␣ ϩ/ϩ mice was infected with JAK2 V617F -GFP retrovirus, and equal numbers of GFP ϩ cells were injected into lethally irradiated syngeneic recipients (whole bone marrow cells containing a total of 10 000 GFP ϩ per mouse, supplemental Figure 4) . By day 48 mildly elevated white blood cell counts were evident in both groups (supplemental Figure 5) . However, GFP ϩ cells in the peripheral blood as an indicator of disease burden steadily increased in the TNF␣ ϩ/ϩ , but not the TNF␣ Ϫ/Ϫ group ( Figure 6A ). The decreased proportion of GFP ϩ cells in the TNF␣ Ϫ/Ϫ mice was not because of an intrinsic long-term engraftment defect of TNF␣ Ϫ/Ϫ mice (supplemental Figure 6 ) nor to a decreased proportion of lineage neg c-kit ϩ Sca-1 ϩ (LKS) cells in the inoculum (supplemental Table 2 ). This suggests that the presence of TNF␣ provides JAK2 V617F -positive cells with a competitive advantage over their JAK2 WT counterparts, thereby promoting their expansion. Consistent with this the TNF␣ Ϫ/Ϫ group showed significantly reduced splenomegaly and a lower proportion of GFP ϩ cells in the spleen and bone marrow ( Figure   6B -C). In comparison with the TNF␣ ϩ/ϩ group, the bone marrow of the TNF␣ Ϫ/Ϫ group demonstrated residual tri-lineage hematopoiesis and fewer atypical megakaryocytes; in spleen and liver MPN infiltrates and reticulin fibrosis were much less pronounced ( Figure  6D ). To confirm that attenuated disease in the absence of TNF␣ was not a strain-specific phenomenon we performed identical transplantation experiments in a mixed C57B/6 background (B6;129S-Tnf tm1Gkl /J), with very similar results (supplemental Figure 7) .
Discussion
Here we identify TNF␣, a negative regulator of hematopoiesis, as a central mediator of clonal expansion in MPN. JAK2 V617F expresssion skews the balance in favor of the JAK2 V617F clone by up-regulating TNF␣ expression while at the same time conferring TNF␣ resistance to JAK2 V617F -positive progenitor cells or even in the case of myeloid cells the paradoxical capacity to respond to TNF␣ with increased proliferation.
We show that JAK2 V617F activity is positively correlated with expression of TNF␣ mRNA, suggesting that JAK2 V617F directly upregulates TNF␣ mRNA. In MPN patients the JAK2 V617F allele burden is positivelycorrelated with TNF expression. It should be noted however that JAK2 V617F -negative MPN patients also have increased plasma TNF concentrations (supplemental Table 1 ), suggesting that that these patients have genetic alterations that lead to JAK2 activation and phenocopy JAK2 V617F in their ability to overproduce TNF. Examples include MPL and LNK mutations. 20, 21 The correlation between JAK2 V617F and TNF expression is further supported by cell line data, which show that HEL cells homozygous for JAK2 V617F have the highest TNF expression and that only in this line TNF is under the control of JAK2 kinase activity, as suggested by pharmacologic inhibition of kinase with 2 different inhibitors. Furthermore, treatment of primary human MNC with JAK2 inhibitors leads to a rapid and sustained down-regulation of TNF expression. While we cannot rule out that the small molecule inhibitors used in our studies regulate TNF by targeting kinases other than JAK2, they strongly suggest that TNF production in MPN is under the control of JAK2. The consequence is a high TNF␣ environment that perturbs physiologic TNF␣ regulation of hematopoiesis.
The second crucial effect of JAK2 V617F on TNF␣ regulation of hematopoiesis is that the mutant confers resistance to TNF␣. We provide several lines of evidence for this. Firstly, overall colony growth from MNC isolated from MPN patients was more resistant to TNF␣ compared with normal MNC. The differential TNF␣ effect was even more pronounced in CD34 ϩ cells, where CFU-GM colony formation in the presence of 10 ng/mL of TNF␣ was reduced to 50% in normal controls, but enhanced to 125% in MPN samples. These data are further supported by our observation that ectopic expression of JAK2 V617F confers TNF␣ resistance to normal as well as Fancc Ϫ/Ϫ progenitor cells. Thirdly, the absence of Figure 5 . Ectopic expression of JAK2 V617F attenuates TNF␣-mediated suppression of myeloid colony formation. JAK2 V617F or empty MIG vector was retrovirally expressed in hematopoietic progenitors (lineage neg c-kit ϩ Sca-1 Ϫ ) from the bone marrow of (A) wild-type and (B) Fancc Ϫ/Ϫ C57B/6J mice. Transduced (GFP ϩ ) cells were plated in methycellulose supplemented with 50 ng/mL mSCF, 10 ng/mL mIL-3 and 3 U/mL hEPO, either with or without TNF␣ (20 ng/mL for wild-type 10 ng/mL for Fancc Ϫ/Ϫ ). Colony number was enumerated at day 12, with colony formation in conditions without TNF␣ set to 100%. TNF␣ attenuated retrovirally induced murine MPN, evidenced by the failure of JAK2 V617F cells (as measured by GFP ϩ ) to expand in the peripheral blood, spleen, and bone marrow. Reduced splenomegaly and less extensive involvement of the spleen with atypical megakaryocytes in the TNF␣ Ϫ/Ϫ group corroborated disease attenuation in the absence of TNF␣. Altogether these data suggest that while MPN is not completely dependent on TNFá, JAK2 V617F cells expand much more robustly in the presence of TNF␣.
The implication of TNF␣ as an important driver of hematologic malignancies has a precedent in the bone marrow failure syndrome FA. FA patients are hypersensitive to and have elevated levels of TNF␣, which promotes clonal evolution and leukemogenesis. [22] [23] [24] [25] The combination of genetic instability and cytokine hypersensitivity creates an environment that supports the selection of leukemic over nonleukemic stem cells. 26, 27 Malignant clones that arise are not only TNF␣-resistant, but give rise to progeny that over-produce TNF␣, further augmenting the selective pressure for expansion of the malignant clone over the hypersensitive parental stem cell pool. Here we provide evidence that a similar paradigm applies to MPN pathogenesis, in which TNF␣ suppresses the preneoplastic pool, while JAK2 V617F expressing cells are protected from or even stimulated by TNF␣ (model depicted in Figure 6E ). The similarities extend to another feature of FA, the TNF hypersensitivity of the preneoplastic stem cell pool. Our observations suggest subtle defects in JAK2 WT stem cells of MPN patients render them hypersensitive to TNF␣ even before the evolution of JAK2 V617F
clones. This notion of an intrinsic defect in preneoplastic JAK2 WT MPN cells is consistent with the decreased CFU-GM formation of progenitor cells from healthy individuals with the MPN predisposing 46/1 haplotype of JAK2 compared with controls without the 46/1 haplotype. 28 If future studies confirm hypersensitivity to TNF␣ as a phenotype that antedates clonal evolution in MPN, knowledge of the underlying causes could help to develop rational risk assessment tools and prevention strategies for MPN. In addition, antagonizing TNF␣ may abrogate the growth advantage of MPN cells and induce clinical responses. BLOOD, 8 DECEMBER 2011 ⅐ VOLUME 118, NUMBER 24 For personal use only. on April 9, 2017. by guest www.bloodjournal.org From
